For research use only. Not for therapeutic Use.
Dimiracetam is an orally active compound, with anti-neuropathic activity. Dimiracetam inhibits hypersensitivity and neurological alterations, and inhibits Sorafenib (HY-10201)-induced neuropathy in cold stimulation rat models[1].
| Catalog Number | M109243 |
| CAS Number | 126100-97-8 |
| Synonyms | 3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione |
| Molecular Formula | C6H8N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9) |
| InChIKey | XTXXOHPHLNROBN-UHFFFAOYSA-N |
| SMILES | C1CC(=O)N2C1NC(=O)C2 |
| Reference | [1]. Di Cesare Mannelli L, et al. A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam. Neurotoxicology. 2015 Sep;50:101-7. [2]. Di Cesare Mannelli L, et al. A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin. Cancer Chemother Pharmacol. 2017 Dec;80(6):1091-1103. |
